Enhanced blood pressure sensitivity to deoxycorticosterone in mice with disruption of bradykinin B2 receptor gene

Hypertension

Volumn 31, Issue 6, 1998, Pages 1278-1283

  Emanueli, Costanza ^c   Fink, Edwin ^c   Milia, Anna Franca ^c   Salis, Maria Bonaria ^c   Conti, Milena ^c   Demontis, Maria Piera ^c   Madeddu, Paolo ^a,b  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c NONE

Author keywords

Blood pressure; Kallikrein kinin system; Mineralocorticoids

Indexed keywords

BRADYKININ B2 RECEPTOR; DEOXYCORTICOSTERONE; GENE PRODUCT; KALLIKREIN; KININ; MINERALOCORTICOID;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; HEART RATE; HYPERTENSION; KALLIKREIN KININ SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; SYSTOLIC BLOOD PRESSURE;

EID: 0031839004     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.6.1278     Document Type: Article

References (30)

1. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension. 1989;13:658-667.
2. Willis LR, Ludens JH, Hook JB, Williamson HE. Mechanisms of natriuretic action of bradykinin. Am J Physiol. 1969;217:F1-F15.
3. Granger JP, Hall JE. Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol. 1985;248:F87-F92.
4. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine and paracrine) in hypertension. Hypertension. 1991;18(suppl I)-I-58-I-69.
5. 2-receptor antagonists. Hypertension. 1991;17:107-115.
6. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H, Williams RR. A gene for high kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13:3-8.
7. Keiser HR, Geller RG, Margolius HS, Pisano JJ. Urinary kallikrein in hypertensive animal models. Fed Proc. 1976;35:199-202.
8. Bianchi G, Barber BR, Torielli L, Ferrari P. The Milan hypertensive strain. In: Swales JD. ed. Textbook of Hypertension. Oxford, England: Blackwell Scientific Publications; 1994:457-461.
9. Carretero OA, Amin VM, Ocholik T, Scicli AG, Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt: a new radioimmunoassay for its direct determination. Circ Res. 1978;42:727-731.
10. Pravanec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L, Kurtz TW. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension. 1991;17:242-246.
11. Margolius HS, Geller R, De Jong W, Pisano JJ, Sjoerdsma A. Urinary kallikrein excretion in hypertension. Circ Res. 1972;30:358-362.
12. Geller RG, Margolius HS, Pisano JJ, Keiser HR. Effects of mineralocorticoids, altered sodium intake and adrenalectomy on urinary kallikrein in rats. Circ Res. 1972;48:728-733.
13. Holland OB, Chud JM, Braunstain H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest. 1980;65: 347-356.
14. Madeddu P, Anania V, Pinna Parpaglia P, Demontis MP, Varoni MV, Fattaccio MC, Glorioso N. Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats. Br J Pharmacol. 1993; 108:651-657.
15. 2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension. 1993;21: 980-984.
16. Lembeck F, Griesbacher T, Eckahardt M, Henke S, Breiphol G, Knolle J. New, long-acting, potent bradykinin antagonists. Br J Pharmacol. 1991; 102:297-304.
17. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breiphol G, Konig W, Knolle J, Scholkens BA. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
18. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons J Biol Chem. 1995;23:13706-13710.
19. 2 receptor knockout mice. Biochem Biophys Res Commun. 1996;224:625-630.
20. 2-receptor gene. Circulation. 1997;96:3570-3578.
21. Fink E, Schill W-B, Fiedler F, Krassnigg F, Geiger R, Shimamoto K. Tissue kallikrein of human seminal plasma is secreted by the prostate gland. Hoppe Seyler's Z Biol Chem. 1985;366:917-924.
22. Rodriguez-Sargent C, Torres-Negron I, Cangiano JL, Martinez-Maldonado M. Deoxycorticosterone hypertension in intact weaning rat without salt loading. Hypertension. 1990;15(suppl I):I-112-I-116.
23. Dubrovnic-Jenik D, Milkovinc S. Regulation of fetal Na-K-ATPase in rat kidney by corticosteroids. Biochim Biophys Acta. 1988;942:227-235.
24. Murray SR, Chao J, Fu-Kuen L, Chao L. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 154(suppl 6):S7-S16.
25. 2 kinin receptors in cultured bovine aortic endothelial cells. J Pharmacol Exp Ther. 1992;262:729-733.
26. 2 receptors of the vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol. 1993;110:71-76.
27. Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, Oh-ishi S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension. 1991;17:806-813.
28. Imamura M, Levi R. Bradykinin promotes exocytotic and carrier-mediated norepinephrine release in myocardial ischemia-reperfusion. Circulation. 1995;92(suppl I):I-568. Abstract.
29. 2-receptors alters the adult cardiovascular phenotype in rats. Hypertension. 1995;25: 453-459.
30. Madeddu P, Glorioso N, Varoni MV, Demontis MP, Fattaccio C, Anania V. Cardiovascular effects of brain kinin receptor blockade in spontaneously hypertensive rats. Hypertension. 1994;23(suppl I):I-189-I-192.